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Abstract Overexpression of strong transcriptional activators
like herpes simplex virion protein 16 (VP16) may lead to non-
specific inhibition of gene expression as a result of the titration of
transcription factors. Here we report that a fusion between the
homeoprotein Hoxa2 and the VP16 activation domain inhibits
transcription from the strong promoter/enhancers of cytomega-
lovirus (CMV) and Rous sarcoma virus (RSV). A similar fusion
involving a Hoxa2 mutant protein that is defective in DNA
binding has no effect on the CMV promoter but increases, rather
than inhibits, the RSV promoter activity. This suggests that
depending on its ability to bind DNA, the VP16 activator can
interact with different sets of cofactors, giving rise to distinct
transcriptional effects. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
Key words: VP16 activation domain; Hoxa2 homeoprotein;
Cytomegalovirus; Rous sarcoma virus;
Transcriptional activation; Squelching e¡ect
1. Introduction
Fusions between a regulatory protein and a potent tran-
scriptional activation domain like those of the yeast GAL4
protein or the virion protein 16 of the herpes simplex virus
type I (VP16) are commonly used to identify targets for the
regulator or to boost the transcriptional activation of a re-
porter gene in transient transfection assays [1]. However,
when expressed at a high level, strong transcriptional activa-
tors have been reported to non-speci¢cally inhibit transcrip-
tion [2^4].
The VP16 activation domain interacts with multiple targets
within the RNA polymerase II transcription initiation com-
plex [5^9], as well as with adapter proteins that make the link
between activation domains and the transcription machinery
[10]. Therefore, it is believed that at a high concentration, the
activator sequesters and titrates out transcription factors like
TBP or TAFs, thereby blocking transcription initiation. This
phenomenon is referred to as a squelching e¡ect.
In the course of the characterization of a target gene for the
murine homeoprotein Hoxa2, we made use of di¡erent fusions
between the VP16 activation domain and Hoxa2 derivatives
(Remacle et al., in preparation). Hoxa2 belongs to the HOM-
C/Hox family of homeoproteins, and contains a well-con-
served 60-amino acid (aa) homeodomain involved in DNA
binding [11]. Here we report that fusion proteins between
the VP16 activation domain and the wild-type Hoxa2 or a
DNA binding-defective mutant di¡erently a¡ect the activity
of the cytomegalovirus (CMV) and the Rous sarcoma virus
(RSV) strong promoters/enhancers, leading to the inhibition,
but in some cases to the activation, of transcription. As
neither of the two proteins alters the CMV or RSV pro-
moter activity in the absence of the VP16 activation domain,
we conclude that the transcriptional e¡ects reported here
account for new distinct consequences of VP16-mediated
squelching.
2. Materials and methods
2.1. Reporter plasmids and expression vectors
Reporter plasmids and expression vectors used in this study are
listed in Table 1. Details of the constructs are available upon request.
Plasmids encoding fusion proteins with the 77-aa activation domain
of VP16 (¢rst residue of the 78-aa sequence omitted) have been ob-
tained by removing the hoxa2 stop codon. The VP16 sequence encod-
ing the activation domain was further ampli¢ed by PCR from
pPGKHoxa1VP16 [17], and inserted as a ClaI-HindIII fragment in
frame with the Hoxa2 or Hoxa2(QN-AA) coding sequence.
2.2. Cell culture and transient transfection
COS7 cells were maintained in Dulbecco’s modi¢ed Eagle’s medium
(Gibco) supplemented with 10% fetal calf serum (PAA Laboratories
GmbH), 100 IU/ml of penicillin and 100 Wg/ml streptomycin (Sigma),
at 37‡C in a humidi¢ed, 5% CO2 atmosphere. Before transfec-
tion, exponentially proliferating cells were trypsinized and 105 cells
were plated per 35-mm culture dish. Cells were transfected by stan-
dard calcium phosphate precipitation procedure, 24 h after plating
[18].
Each cotransfection experiment was performed with a constant
amount of 10.2 Wg of DNA containing, when appropriate, 4 Wg of
the luc-based reporter (pTKluc or pAdMLluc), 2 Wg of the Hoxa2
derivative expression vector, 0.2 Wg of the lacZ internal standard
plasmid (pCMVlacZ, pRSVlacZ, pSVK3lacZ or pCD-SRKlacZ),
and carrier DNA to complement.
2.3. L-Galactosidase and luciferase assays
Cells were harvested 48 h after transfection for enzymatic assays.
Lysis and enzymatic activity dosages were performed with the L-gal
reporter gene assay (chemiluminescent) kit (Roche) and the luciferase
reporter gene assay (high sensitivity) kit (Roche).
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3. Results
3.1. Fusion protein Hoxa2VP16 modi¢es the transcriptional
activity of the CMV and RSV strong promoters in
transient transfection assays
In the context of analyzing a Hoxa2-responsive enhancer
(Remacle et al., in preparation), the e¡ect of the Hoxa2 and
Hoxa2VP16 fusion proteins was examined in cotransfection
with a control reporter plasmid in which the ¢re£y luc gene
is under the control of the thymidine kinase (TK) promoter
(pTKluc) or the adenovirus-2 major late (AdML) promoter
(pAdMLluc). To avoid experimental variations due to varia-
ble transfection e⁄ciencies, an internal standard reporter con-
taining the lacZ gene under the control of the CMV
(pCMVlacZ) or RSV (pRSVlacZ) promoter was also added
in the cotransfection experiments. Luciferase activity was then
normalized to that of L-galactosidase.
Transfection of the Hoxa2 expression vector in combina-
tion with pTKluc or pAdMLluc did not modify the level of
normalized luciferase activity as compared to the experiments
in which the Hoxa2 plasmid was omitted (reference value of
1; Fig. 1A). In contrast, transfection of the vector expressing
the Hoxa2VP16 fusion protein resulted in a dramatic increase
in the ratio between the luciferase and L-galactosidase activ-
ities, whatever the reporter (pAdMLluc or pTKluc) and the
standard (pCMVlacZ or pRSVlacZ) plasmids used (Fig. 1B).
This indicates that the VP16 moiety of the Hoxa2VP16 pro-
tein either activates luc expression or represses that of lacZ, or
both.
To discriminate between these two possibilities, cotransfec-
tion experiments were performed with two other reporter plas-
mids, in which the lacZ reporter gene is under the control of
either the SV40 early promoter (pSVK3lacZ) or the SV40
early promoter combined with the R-U5 enhancer of
HTLV-1 (pCD-SRKlacZ). With these two lacZ reporter plas-
mids, the addition of either Hoxa2 or Hoxa2VP16 resulted in
only a slight change in the luciferase/L-galactosidase ratio
(Fig. 1A,B). This implies that Hoxa2VP16 has no e¡ect on
Table 1
Reporter plasmids and expression vectors used in this study
Reporter plasmid Promoter Reporter gene Origin
pTKluc TKa lucb pXP2 [12]
pAdMLluc AdMLc luc [13]
pCMVlacZ CMVd lacZe pCMX-PL1 [14]
pRSVlacZ RSVf lacZ [15]
pSVK3lacZ SV40g lacZ pSVK3; Pharmacia
pCD-SRKlacZ HTLVILTR-SV40h lacZ pCD-SRK [16]
Expression vector Promoter Encoded Hoxa2 derivative Origin
pCMVHoxa2 CMV Hoxa2 wild type pCMX-PL1 [14]
pCMVHoxa2(QN-AA) CMV Hoxa2(QN-AA)i pCMX-PL1 [14]
pCMVHoxa2VP16 CMV Hoxa2: :VP16j pCMX-PL1 [14,17]
pCMVHoxa2(QN-AA)VP16 CMV Hoxa2(QN-AA): :VP16k pCMX-PL1 [14,17]
aFrom herpes simplex I thymidine kinase (from nt 3105 to +51).
bFire£y luciferase gene.
cFrom adenovirus-2 major late promoter (from nt 333 to +33).
dCytomegalovirus major immediate-early promoter.
eEscherichia coli lacZ gene.
f Rous sarcoma virus long terminal repeat promoter.
gSV40 early promoter.
hR-U5 segment of the long terminal repeat of human T-cell leukemia virus type I and SV40 early promoter.
iHoxa2 with homeodomain residues Q50 and N51 converted into A50 and A51.
jFusion protein between Hoxa2 and the VP16 activation domain.
kFusion protein between the Hoxa2(QN-AA) mutant and the VP16 activation domain.
Fig. 1. The Hoxa2VP16 protein induces changes in relative reporter
activities. Di¡erent luc and lacZ reporter constructs were transfected
in COS7 cells in combination with an expression vector for (A)
Hoxa2 and (B) Hoxa2VP16. For each combination of reporter plas-
mids, the relative luciferase activity obtained in the absence of ex-
pression vector is set at 1. Each series of experiments has been re-
peated more than twice, in each experiment sample size is 2 for
each plasmid combination.
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the promoters carried by the pTKluc, pAdMLluc, pSVK3lacZ
or pCD-RSKlacZ reporter plasmids, and that the signi¢cant
increase in normalized activities observed with pCMVlacZ
and pRSVlacZ arises from a strong inhibition of the CMV
and RSV promoters, rather than the activation of the AdML
or TK105 promoters.
3.2. The DNA binding-defective Hoxa2(QN-AA)VP16 fusion
protein activates rather than inhibits RSV promoter
activity
The proteins of the Hox family share a very well conserved
homeodomain. Contacts between the homeodomain and
DNA involve several amino acids, among which a glutamine
at position 50 and an asparagine at position 51 are perfectly
conserved within the Hox family. These residues have been
shown to make critical contacts with bases within the
TNATNN sites recognized by homeoproteins [11,19]. Both
residues have pivotal roles in the binding speci¢city of the
proteins, and contribute to their a⁄nity for the DNA [20^22].
Cotransfection experiments involving combinations of
pTKluc, pAdMLluc, pCMVlacZ and pRSVlacZ reporters
were performed with vectors encoding the Hoxa2(QN-AA)
and Hoxa2(QN-AA)VP16 mutant proteins (Fig. 2). In these
proteins residues 50 and 51 of the homeodomain have been
converted to alanines.
Similarly to wild-type Hoxa2, the Hoxa2(QN-AA) mutant
protein alone did not change or only slightly altered the lu-
ciferase/L-galactosidase ratio when combined with the di¡er-
ent reporters (Fig. 2A). By contrast, cotransfections per-
formed with the Hoxa2(QN-AA)VP16 fusion protein yielded
di¡erent results than those reported above for Hoxa2VP16
(Fig. 2B). Hoxa2(QN-AA)VP16 only weakly a¡ected the lu-
ciferase/L-galactosidase ratio when the lacZ gene expression
was driven by the CMV promoter, whereas it caused a severe
drop in this ratio when the pRSVlacZ standard vector was
used (Fig. 2B). This indicates that, unlike Hoxa2VP16, the
mutant Hoxa2(QN-AA)VP16 fusion protein has no or little
e¡ect on the CMV promoter, and that it activates rather than
inhibits transcription from the RSV promoter. Since the two
proteins di¡er by only two amino acid residues in the Hoxa2
homeodomain, it is likely that their di¡erent e¡ects on tran-
scription are direct or indirect consequences of their DNA
binding properties.
Fig. 2. The Hoxa2(QN-AA)VP16 fusion protein induces an increase
in lacZ expression mediated by the RSV promoter. Di¡erent luc
and lacZ reporter constructs were transfected in COS7 cells in com-
bination with an expression vector for (A) Hoxa2(QN-AA) and
(B) Hoxa2(QN-AA)VP16. For each combination of reporter plas-
mids, the relative luciferase activity obtained in the absence of ex-
pression vector is set at 1. Sample size is 2 for each plasmid combi-
nation.
Fig. 3. The level of transcriptional activation/repression mediated by
VP16 fusion proteins varies according to the amount of expression
vector transfected. Cotransfection experiments (COS7 cells) have
been performed with pAdMLluc, pCMVlacZ, pRSVlacZ, and in-
creasing amounts of pCMVHoxa2 (A), pCMVHoxa2VP16 (A),
pCMVHoxa2(QN-AA) (B), or pCMVHoxa2(QN-AA)VP16 (B),
ranging from 0.05 to 4 Wg of DNA for 105 cells. For each combina-
tion of reporter plasmids, the relative luciferase activity obtained in
the absence of expression vector is set at 1. Sample size is 2 for
each combination of plasmids tested.
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3.3. The level of transcriptional activation/repression mediated
by VP16 fusion proteins increases with the amount of
transfected expression vector
The squelching e¡ects caused by strong transcriptional ac-
tivators may depend on the abundance of the activator within
the cell. To test this, cotransfection experiments were per-
formed with increasing amounts of plasmids encoding the
Hoxa2, Hoxa2(QN-AA), Hoxa2VP16 or Hoxa2(QN-AA)-
VP16 proteins (Fig. 3). As expected, adding up to 4 Wg of
the Hoxa2 and Hoxa2(QN-AA) expression vectors only led
to minor £uctuations in the ratio between reporter activities
(Fig. 3A,B).
For the Hoxa2VP16 fusion protein, the luciferase/L-galac-
tosidase ratio measured in the presence of the CMVlacZ re-
porter progressively increased in relation to the amount of
expression vector, to reach a value up to 20 times higher
than the background level (Fig. 3A). With the RSVlacZ re-
porter, addition of up to 0.5 Wg of Hoxa2VP16 vector DNA
induced a 5^7-fold increase in the luciferase/L-galactosidase
ratio, with no further increase when more expression vector
was added.
Transfection of increasing amounts of expression vector for
the Hoxa2(QN-AA)VP16 mutant did not strongly a¡ect the
relative luciferase activity when lacZ was expressed under the
control of the CMV promoter (Fig. 3B). Inversely, with the
RSVlacZ reporter, increasing amounts of Hoxa2(QN-
AA)VP16 induced a progressive decrease of the luciferase/L-
galactosidase ratio. Upon transfection of 2 Wg of the Hoxa2-
(QN-AA)VP16 expression vector, the ratio was 10 times lower
than in the absence of Hoxa2(QN-AA)VP16.
Altogether these results con¢rm that the activity of di¡erent
promoters can be either enhanced, inhibited or una¡ected as a
consequence of the expression of the VP16 activator. Further-
more, variations in promoter activity can be di¡erent, or even
opposite, depending on the DNA binding properties of the
activator. Finally, the relationship between the amount of
expression vector and the change in promoter activity also
appears to be di¡erent according to the promoter and prob-
ably to the VP16 fusion protein. Indeed, the ratio between the
measured enzymatic activities can either reach a plateau or
continuously increase, or decrease, upon addition of increas-
ing amounts of expression vector.
4. Discussion
The data presented here provide new cases and new con-
sequences of VP16-mediated squelching e¡ects. Using di¡er-
ent combinations of luciferase and L-galactosidase reporter
plasmids, we found that the reporters’ relative activities
changed upon addition of VP16 fusion proteins when the
lacZ gene was transcribed from either the CMV or the RSV
promoter. Furthermore, whereas the Hoxa2VP16 protein
caused a decrease in CMV- and RSV-driven lacZ expression,
the DNA binding-defective mutant, Hoxa2(QN-AA)VP16,
had no or a slight e¡ect on the CMV promoter, but induced
an increase in RSV promoter activity. In similar conditions,
Hoxa2 and Hoxa2(QN-AA) proteins did not a¡ect the rela-
tive reporter activities.
We think that these transcriptional e¡ects associated with
Hoxa2VP16 and Hoxa2(QN-AA)VP16 result from VP16-as-
sociated ‘squelching’ rather than from the speci¢c interaction
of Hoxa2 derivatives with cognate sites that would reside in
the CMV or RSV loci. Supporting this view, (i) the Hoxa2
protein does not appear to a¡ect CMV- and RSV-mediated
transcription; (ii) in experiments similar to those presented
here, Hoxa2 and Hoxa2VP16 properly activate (rather than
inhibit) a reporter gene controlled by Hox-responsive se-
quence elements (Matis et al., unpublished data); and consis-
tently, (iii) Hoxa2(QN-AA)VP16 which cannot bind to Hoxa2
recognition sites has no e¡ect on a proper speci¢c target gene
(Matis et al., unpublished data).
Altogether, our data show, ¢rstly, that transcriptional in-
terference mediated by high amounts of the VP16 activation
domain a¡ects the strong CMV and RSV promoters that are
often used in internal standard constructs to normalize trans-
fection assays. Conversely, the activity of AdML and TK105
promoters as well as that of the SV40 early promoter are not
a¡ected by VP16. This means that, in our assay, the VP16
domain does not interfere with the basal transcription machi-
nery, but rather with accessory factors required for speci¢c
promoters/enhancers.
Secondly, the transfection of the Hoxa2VP16 vector caused
the ratio between the luciferase and L-galactosidase activities
to reach a plateau when the lacZ gene is controlled by the
RSV promoter. This ratio did not vary further upon trans-
fection of higher amounts of expression vector. Inversely, this
enzymatic ratio continuously increased upon addition of in-
creasing amounts of this expression vector to transfected
pCMVlacZ reporter plasmid. Therefore, the relationship be-
tween the amount of transfected vector encoding the VP16
fusion protein and the change in promoter activity appears
to be di¡erent according to the promoter.
Thirdly, our results stressed that, depending on the fusion
protein, the VP16 activation domain can induce an inhibitory
or a stimulatory e¡ect on transcription. The Hoxa2VP16 pro-
tein that has an intact homeodomain caused a typical inhib-
itory squelching e¡ect on both the CMV and RSV promoters.
By contrast, the Hoxa2(QN-AA)VP16 mutant, which is im-
paired for its ability to bind DNA, activated RSV-mediated
transcription and had no or little e¡ect on the CMV pro-
moter. The Hoxa2VP16 and Hoxa2(QN-AA)VP16 fusion pro-
teins di¡er by only two amino acid residues in the Hoxa2
homeodomain. These residues are involved in the binding
and the recognition of DNA sites. We cannot exclude the
possibility that the substitution of the glutamine and aspara-
gine residues by alanines may impair other properties than the
DNA binding of the protein. However, these amino acids that
are perfectly conserved among the Hox proteins do not ap-
pear to be involved in other activities of these proteins, and in
particular they are not involved in the interaction between
Hox and their known cofactors [19,23,24]. Therefore, it can
be assumed that the di¡erent e¡ects caused by the expression
of Hoxa2VP16 or Hoxa2(QN-AA)VP16 on CMV and RSV
activity are direct or indirect consequences of their distinct
DNA binding properties.
Glutamine 50 and asparagine 51 have been shown to con-
tact the DNA base pairs, and to critically contribute to the
binding speci¢city of the Hox proteins [11,20^22]. However,
even if converting these residues into alanines may a¡ect the
a⁄nity of the protein for the DNA, it is likely that, within a
cell, the mutant proteins will still bind to DNA, but in a more
relaxed fashion [22]. Therefore, the distinct squelching e¡ects
induced by Hoxa2VP16 and Hoxa2(QN-AA)VP16 may be the
consequence of the di¡erent distribution of these two proteins
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on the DNA. Alternatively, the decrease in DNA binding
a⁄nity displayed by the mutant may be such that it preferen-
tially interacts with cofactor proteins rather than with DNA,
which in turn would lead to the distinct e¡ects observed on
the transcriptional activity. Our data do not allow us to favor
one of the above hypotheses, and additional experiments are
required to sort out how di¡erences in DNA binding may
a¡ect VP16-mediated squelching.
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